Shares of prostate cancer drugmaker Medivation (MDVN)closed down 6% after reporting fourth-quarter earnings, despite handily beating expectations. Sales of its flagship product Xtandi racked up $57 million in its first full quarter. Its conference call was full of questions regarding the launch, as well as discussion over a controversial research report. Watch as health-care analyst David Williamson takes you through the day's events.